Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wuhan Healthgen BiotechnologySHSE:688765 +4.66%19 PS Ratio is 319.36 as of Jul. 16, 2026, which is 28% below its 10-year median of 444.65. GuruFocus rates SHSE:688765 with a GF Score™ of 19/100. The stock has 7 warning signs investors should review. Among 955 Drug Manufacturers companies, Wuhan Healthgen Biotechnology ranks worse than 99.06% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Wuhan Healthgen Biotechnology's share price is ¥54.61.
Wuhan Healthgen Biotechnology's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ¥0.17. Hence, Wuhan Healthgen Biotechnology's PS Ratio for today is 319.36.
The historical rank and industry rank for Wuhan Healthgen Biotechnology's PS Ratio or its related term are showing as below:
SHSE:688765'
s PS Ratio Range Over the Past 10 Years
Min: 251.23 Med: 444.65 Max: 1420.11
Current: 319.38
During the past 12 years, Wuhan Healthgen Biotechnology's highest PS Ratio was 1420.11. The lowest was 251.23. And the median was 444.65.
SHSE:688765's PS Ratio is ranked worse than 99.06% of 955
companies
in the Drug Manufacturers industry
Industry Median: 2.35
vs SHSE:688765: 319.38
During the past 12 years, Wuhan Healthgen Biotechnology's highest 3-Year average Revenue per Share Growth Rate was 86.30% per year. The lowest was -40.50% per year. And the median was 16.80% per year.
Back to Basics: PS Ratio
Wuhan Healthgen Biotechnology (SHSE:688765) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Wuhan Healthgen Biotechnology PS Ratio Related Terms
Wuhan Healthgen Biotechnology PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Wuhan Healthgen Biotechnology's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wuhan Healthgen Biotechnology PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Wuhan Healthgen Biotechnology's PS Ratio distribution charts can be found below:
* The bar in red indicates where Wuhan Healthgen Biotechnology's PS Ratio falls into.
Wuhan Healthgen Biotechnology PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Wuhan Healthgen Biotechnology's Share Price of today is ¥54.61. Wuhan Healthgen Biotechnology's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.17.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Wuhan Healthgen Biotechnology (SHSE:688765) has a PS Ratio of 319.36 as of Jul. 16, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Wuhan Healthgen Biotechnology and its competitors. This is 28% below median its historical median of 444.65. Over the past decade, Wuhan Healthgen Biotechnology's PS Ratio has ranged from 251.23 to 1,420.11. According to the industry distribution chart, Wuhan Healthgen Biotechnology ranks #946 out of 955 companies in the Drug Manufacturers industry, placing it in the top 99.1%.
Is Wuhan Healthgen Biotechnology's PS Ratio too high?
Wuhan Healthgen Biotechnology's current PS Ratio of 319.36 is 28% below median its 10-year median of 444.65. Over the past 10 years, this metric has ranged from a low of 251.23 to a high of 1,420.11. The Drug Manufacturers industry median PS Ratio is 2.35. Wuhan Healthgen Biotechnology's value of 319.36 is 13489.8% above this industry median. Based on the distribution chart, Wuhan Healthgen Biotechnology ranks #946 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Wuhan Healthgen Biotechnology has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Wuhan Healthgen Biotechnology's PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Wuhan Healthgen Biotechnology ranks #946 out of 955 companies for PS Ratio. This places Wuhan Healthgen Biotechnology in the lower half of its industry. The industry median PS Ratio is 2.35. Wuhan Healthgen Biotechnology's value of 319.36 is 13489.8% above this benchmark. Historically, Wuhan Healthgen Biotechnology's own PS Ratio has ranged from 251.23 to 1,420.11 over the past decade. While the company's 10-year median is 444.65 vs. the industry median of 2.35, Wuhan Healthgen Biotechnology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.35, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wuhan Healthgen Biotechnology's current PS Ratio of 319.36 is 13489.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Wuhan Healthgen Biotechnology and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wuhan Healthgen Biotechnology's current PS Ratio is 319.36, which is 28% below median its own 10-year median of 444.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuhan Healthgen Biotechnology stock overvalued right now?
Wuhan Healthgen Biotechnology (SHSE:688765) has a current PS Ratio of 319.36. The current PS Ratio is 319.36, which is 28% below median its 10-year median of 444.65 and 13489.8% above the Drug Manufacturers industry median of 2.35. Wuhan Healthgen Biotechnology's overall GF Score™ is 19/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Wuhan Healthgen Biotechnology (SHSE:688765), the current PS Ratio is 319.36 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Wuhan Healthgen Biotechnology Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688765 has been successfully added to your 
